Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

FED × relugolix × Genitourinary × Clear all

Phase

Status

Sponsor Class

OTHER 26 INDUSTRY 10 NETWORK 2 FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1 Neoplasm Metastasis 1

Interventions

enzalutamide 4 pembrolizumab 3 apalutamide 3 Docetaxel 3 Abiraterone Acetate 3 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3 abiraterone 2 Testosterone 2 Prednisone 2 Leuprolide 2 Cholecalciferol 2 Celecoxib 2 Androgen Antagonists 2 sulforaphane 1 relugolix 1 olaparib 1 nilutamide 1 histrelin 1 gallium 68 PSMA-11 1 copanlisib 1 capivasertib 1 bicalutamide 1 avelumab 1 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1 Yoga 1 Triptorelin Pamoate 1 Tablets 1 Simvastatin 1 Sildenafil Citrate 1 Radiosurgery 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04787744 2026-04-08

VA STARPORT

VA Office of Research and Development

Phase 2/3 Recruiting

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡